Li Xiaoyan1, Zang Shengbing1, Zhang Yu1, Zheng Lin1, Lin Chengjie2, Liu Jingfeng3, Huang Aimin4. 1. Department of Pathology and Institute of Oncology, Fujian Medical University, Fuzhou 350004, PR China. 2. Liver Center, the First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, PR China. 3. Liver Center, the First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, PR China. Electronic address: drjingfeng@126.com. 4. Department of Pathology and Institute of Oncology, Fujian Medical University, Fuzhou 350004, PR China. Electronic address: draimin@163.com.
Abstract
BACKGROUND AND AIM: To explore the expression and role of activating transcription factor 3 in human hepatocellular carcinoma. METHODS: Immunohistochemistry, Western blot assay and Real-time PCR were used to evaluate activating transcription factor 3 protein and gene level in HCC clinical samples. RESULTS: Activating transcription factor 3 expression is lowest in HCC, and the protein level is lower in patients with capsule invasion, while there is no association with other main clinical pathological features. CONCLUSIONS: Low expression of ATF3 may function as a tumor suppressor during human hepatocellular oncogenesis and targeting ATF3 pathway might be beneficial for anti-HCC therapy.
BACKGROUND AND AIM: To explore the expression and role of activating transcription factor 3 in humanhepatocellular carcinoma. METHODS: Immunohistochemistry, Western blot assay and Real-time PCR were used to evaluate activating transcription factor 3 protein and gene level in HCC clinical samples. RESULTS:Activating transcription factor 3 expression is lowest in HCC, and the protein level is lower in patients with capsule invasion, while there is no association with other main clinical pathological features. CONCLUSIONS: Low expression of ATF3 may function as a tumor suppressor during human hepatocellular oncogenesis and targeting ATF3 pathway might be beneficial for anti-HCC therapy.